本文梳理了数字疗法概念演变过程和数字疗法产业发展情况,总结了数字疗法的主要特点,以美国、德国、英国、中国为例,探究四国数字疗法的医保支付现状,介绍数字疗法从上市到纳入医保支付的相关政策内容。研究发现,四国在数字疗法医保支付方面均进行了不同程度的探索,其中美国、德国在支付流程上有所创新,但整体来看,其医保支付制度设计仍有不足。因此,本文建议未来可探索以证据为准绳,综合考虑消费者意愿,设计更加完善的数字疗法医保支付政策。
Abstract
This study outlines the evolution of the concept of digital therapeutics (DTx) and the development of DTx industry, summarizes the main features of DTx, and takes the United States, Germany, the United Kingdom, and China as examples to explore the current situation of medical insurance payment in these countries, as well as the main policies of DTx from marketing to inclusion in medical insurance payment. All the four countries have begun exploration of health insurance payment for DTx at varying degrees, among which the United States and Germany have made many innovations in the payment flow. However, the development of health insurance payment still lags behind the development of DTx products as a whole, and there are still deficiencies in the design of the system. In the future, we can design more comprehensive health insurance payment for DTx based on evidence, taking into account the willingness of consumers.
关键词
数字疗法 /
医疗保险 /
国际经验
Key words
digital therapeutics (DTx) /
medical insurance /
international experience
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] WHO.Noncommunicable diseases[EB/OL].(2022-09-16)[2023-07-20].https://www.who.int/en/news-room/fact-sheets/detail/noncommunicable-diseases.
[2] MITCHELL J.Increasing the cost-effectiveness of telemedicine by embracing e-health[J].Journal of telemedicine and telecare, 2000,6:16-19.
[3] OH H, RIZO C, ENKIN M, et al.What is eHealth (3):a systematic review of published definitions[J].Journal of medical Internet research, 2005, 7(1):e1.
[4] EYSENBACH G.What is e-health?[J].Journal of medical Internet research, 2001, 3(2):E20.
[5] LAXMINARAYAN S, ISTEPANIAN R S H.Unwired e-med:the next generation of wireless and Internet telemedicine systems[J].IEEE transactions on information technology in biomedicine, 2000,4(3):189-193.
[6] SILVA B M C, RODRIGUES J J P C, de la TORRE DÍEZ I, et al.Mobile-health:a review of current state in 2015[J].Journal of biomedical informatics, 2015,56:265-272.
[7] MOSES J C, ADIBI S, WICKRAMASINGHE N, et al.Smartphone as a disease screening tool:a systematic review[J].Sensors (Basel), 2022,22(10).
[8] DTA.Digital health, digital medicine, digital therapeutics (DTx):what's the difference?[EB/OL].(2019-11-11)[2023-05-23].https://dtxalliance.org/2019/11/11/digital-health-digital-medicine-digital-therapeutics-dtx-whats-the-difference/.
[9] WHO.Global strategy on digital health2020-2025[EB/OL].(2021-08-18)[2023-05-23].https://www.who.int/docs/default-source/documents/gs4dhdaa2a9f352b0445bafbc79ca799dce4d.pdf.
[10] DiME.Defining digital medicine[EB/OL].(2021-02-17)[2023-08-01].https://dimesociety.org/about-us/defining-digital-medicine/.
[11] FDA.FDA permits marketing of mobile medical application for substance use disorder[EB/OL].(2017-09-14)[2023-08-01].https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-mobile-medical-application-substance-use-disorder.
[12] 刘少金,刘玉玲,朱子航,等.数字疗法行业发展态势分析及建议[J].江西科学,2022,40(6):1194-1202.
[13] 动脉网.全球数字疗法产业报告(2022)[EB/OL].(2022-05-30)[2023-08-01].https://www.vbdata.cn.
[14] BERGER T, URECH A, KRIEGER T, et al.Effects of a transdiagnostic unguided Internet intervention ('velibra') for anxiety disorders in primary care:results of a randomized controlled trial.[J].Psychological medicine, 2017, 47(1):67-80.
[15] DTA.DTx by country[EB/OL].[2023-11-21].https://dtxalliance.org/understanding-dtx/dtx-by-country/.
[16] 王帅,杜春淼,沙宪政.浅谈国内移动医疗软件监管工作[J].中国医疗器械杂志,2015(5):353-355.
[17] FDA.Policy for device software functions and mobile medical applications:guidance for industry and Food and Drug Administration staff[EB/OL].(2022-09-28)[2023-08-01].https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-device-software-functions-and-mobile-medical-applications.
[18] 陈永法,邹泉.美国FDA移动医疗应用监管探究[J].中国卫生信息管理杂志,2017,14(6):813-816+837.
[19] 马艳彬,白旭东,金丹,等.美国FDA数字健康产品监管研究与启示[J].中国医学装备, 2022,19(9):181-188.
[20] FDA.Digital Health Innovation Action Plan[EB/OL].(2020-03-26)[2023-08-01].https://www.fda.gov/media/106331/download.
[21] 严舒,徐东紫,欧阳昭连.美国人工智能医疗器械监管与应用分析[J].中国医疗设备,2021,36(2):117-122.
[22] FDA.Premarket Notification 510(k)[EB/OL].(2022-10-30)[2023-05-23].https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k.
[23] FDA.Breakthrough Devices Program[EB/OL].(2023-03-28)[2023-06-29].https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program.
[24] CMS.Medicare coverage of innovative technologies (MCIT)[EB/OL].(2021-09-13)[2023-11-06].https://www.cms.gov/blog/medicare-coverage-innovative-technologies-mcit.
[25] CMS.Notice with comment-transitional coverage for emerging technologies (CMS-3421-NC)[EB/OL].(2023-06-22)[2023-08-01].https://www.cms.gov/newsroom/fact-sheets/notice-comment-transitional-coverage-emerging-technologies-cms-3421-nc.
[26] DEUTSCHER BUNDESTAG.Gesetz für eine bessere versorgung durch digitalisierung und innovation (Digitale-Versorgung-Gesetz-DVG)[EB/OL].(2019-11-06)[2023-08-01].https://dip.bundestag.de/vorgang/gesetz-f%C3%BCr-eine-bessere-versorgung-durch-digitalisierung-und-innovation-digitale-versorgung-gesetz/251761.
[27] BMJ.Verordnung über das Verfahren und die Anforderungen zur Prüfung der Erstattungsfähigkeit digitaler Gesundheitsanwendungen in der gesetzlichen Krankenversicherung (Digitale Gesundheitsanwendungen-Verordnung - DiGAV)[EB/OL].(2022-12-20)[2023-08-01].https://www.gesetze-im-internet.de/digav/BJNR076800020.html.
[28] BfArM.The fast-track process for digital health applications (DiGA) according to Section 139e SGB V[EB/OL].(2020-08-07)[2023-08-01].https://www.bfarm.de/SharedDocs/Downloads/EN/MedicalDevices/DiGA_Guide.html.
[29] GENSOROWSKY D, WITTE J, BATRAM M, et al.Market access and value-based pricing of digital health applications in Germany[J].Cost effectiveness and resource allocation, 2022,20(1):25.
[30] POWELL A, TOROUS J.A patient-centered framework for measuring the economic value of the clinical benefits of digital health apps:theoretical modeling[J].JMIR ment health, 2020,7(10):e18812.
[31] DTA-HW.DTx policy pathways:the evolving scenario in Europe[EB/OL].(2023-06-29)[2023-11-11].https://3783108.fs1.hubspotusercontent-na1.net/hubfs/3783108/DTxPolicyReport/DTA-HW_DTxPolicyPathways_June23.pdf.
[32] 李国瑜,姚强,刘小君,等.我国“互联网+”医疗服务医保支付政策研究[J].卫生经济研究, 2023,40(05):43-46.
[33] 吴胤歆,刘文彬.新增医疗服务项目纳入医保目录管理机制探索[J].中国卫生经济,2019,38(3):35-37.
基金
北京市科技计划课题“冠脉血流储备分数计算软件卫生经济学评估”（z211100003521014）
